晚期肺癌化疗免疫治疗前使用皮质类固醇的生存结局
该回顾性队列研究纳入316例转移性非小细胞肺癌或广泛期小细胞肺癌患者,比较化疗免疫治疗(CICPI)前28天内使用 versus 未使用全身性皮质类固醇的生存结局。经逆概率加权调整后,CICPI治疗前使用皮质类固醇与未使用者相比,总生存、真实世界进展和真实世界无进展生存均无显著差异,提示有指征时不应因使用皮质类固醇而回避CICPI。
要点
- CICPI前28天内使用全身性皮质类固醇未与更差的总生存相关。
- 皮质类固醇使用与否的真实世界进展和真实世界无进展生存无显著差异。
- 有临床指征时,不应因担心影响疗效而避免使用皮质类固醇。
核心结论
- 在转移性非小细胞肺癌或广泛期小细胞肺癌患者中,CICPI开始前28天内使用全身性皮质类固醇与未使用者相比,总生存、真实世界进展和真实世界无进展生存均无显著差异。
研究设计与样本
- 回顾性队列研究,使用电子健康记录,纳入2015年4月1日至2018年1月31日接受化疗或2018年2月1日至2019年8月31日接受CICPI的mNSCLC或ES-SCLC患者,排除有可靶向驱动突变的患者。
- 共纳入316例患者,中位年龄67岁(IQR 61-73),男性156例(49%),其中化疗组228例,CICPI组88例。
- 采用逆概率治疗加权(IPW)调整潜在混杂因素。
主要发现
- 以化疗组未使用皮质类固醇者为共同参照,CICPI组使用皮质类固醇者的死亡风险IPW-HR=0.67(95%CI 0.35-1.28),CICPI组未使用者IPW-HR=0.88(95%CI 0.55-1.42),组间比较p=0.49。
- 真实世界进展风险:CICPI组使用皮质类固醇者IPW-HR=0.35(95%CI 0.12-0.99),未使用者IPW-HR=0.41(95%CI 0.24-0.70),组间比较p=0.77。
- 真实世界无进展生存:CICPI组使用皮质类固醇者IPW-HR=0.56(95%CI 0.29-1.09),未使用者IPW-HR=0.69(95%CI 0.46-1.03),组间比较p=0.59。
临床怎么用
- 对于有明确指征的晚期肺癌患者,在启动CICPI前使用全身性皮质类固醇不应成为推迟或放弃免疫治疗的依据。
- 临床决策仍需结合皮质类固醇的使用指征、剂量和疗程个体化评估。
局限性
- 回顾性研究设计,样本量有限(共316例,CICPI组仅88例)。
- 基线皮质类固醇使用定义为CICPI前28天内,未区分剂量和疗程。
- 研究排除了有可靶向驱动突变的患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: How corticosteroid use affects treatment response to chemotherapy and immune-checkpoint inhibitors (CICPIs) remains unknown. We assessed how systemic corticosteroid exposure before CICPI modifies the effect of CICPI on outcomes among patients with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC). METHODS: We conducted a retrospective cohort study using electronic health records to examine patients with mNSCLC or ES-SCLC who received chemotherapy (CT) between 1st April 2015 and 31st January 2018 or CICPI between 1st February 2018 and 31st August 2019. We excluded those with an actionable driver mutation. Baseline corticosteroid use was defined as systemic corticosteroids within 28 days before the initiation of CT or CICPI, not including premedications. Coprimary outcomes included overall survival (OS), real-world progression (rwP), and real-world progression-free survival (rwPFS) in CICPI-treated corticosteroid users versus non-users. We used inverse probability of treatment weighting (IPW) to adjust for potential confounding. RESULTS: The cohort of 316 patients (median [interquartile range] age, 67 [61-73] years; 156 [49%] male) included 228 CT-treated and 88 CICPI-treated patients. After applying IPW, characteristics were well-balanced between the CT and CICPI groups, and steroid users and non-users. Using CT-treated steroid non-users as a common comparator, CICPI-treated steroid users were as likely as CICPI-treated steroid non-users to die (users IPW hazard ratio [HR] = 0.67, 95% CI = 0.35-1.28 versus non-users IPW-HR = 0.88, 95% C = I0.55-1.42; p = 0.49), have rwP (IPW-HR = 0.35, 95% C = I0.12-0.99 versus IPW-HR = 0.41, 95% C = I0.24-0.70; p = 0.77), or experience rwPFS (IPW-HR = 0.56, 95% C = I0.29-1.09 versus IPW-HR = 0.69, 95% CI0.46-1.03; p = 0.59). CONCLUSION: Corticosteroid use before CICPIs was not associated with worse outcomes, suggesting that corticosteroids should be used with CICPIs when indicated.
引用
- Sorial MN, Huynh JP, Azzoli CG, et al. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. Eur J Cancer. 2021. PMID: 33431285. doi:10.1016/j.ejca.2020.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。